Search

Displaying results 3351 - 3360 of 8196 in total
  1. Drug

    Meningococcal polysaccharide vaccine group Y

    go.drugbank.com/drugs/DB13888
    ApprovedInvestigational

    It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup Y.

  2. Drug

    Cidofovir

    go.drugbank.com/drugs/DB00369
    ApprovedInvestigational

    Cidofovir is an injectable antiviral medication employed in the treatment of cytomegalovirus (CMV) retinitis in patients diagnosed with AIDS.

  3. Drug

    Fosdenopterin

    go.drugbank.com/drugs/DB16628
    Approved

    Molybdenum cofactor deficiency (MoCD) is an exceptionally rare autosomal recessive disorder resulting in a deficiency of three molybdenum-dependent enzymes: sulfite oxidase (SOX), xanthine dehydrogenase

  4. Drug

    ND1251

    go.drugbank.com/drugs/DB05132
    Experimental

    ND1251 is an orally active phosphodiesterase-4 (PDE4) inhibitor, a mechanism clinically proven to play a role in alleviating symptoms of depression.

  5. Drug

    Pacritinib

    go.drugbank.com/drugs/DB11697
    ApprovedInvestigational

    [L40793] The underlying cause of primary MF is unknown, but secondary MF can arise in patients with a history of polycythemia vera or essential thrombocythemia. … Pacritinib is an inhibitor of both wild-type and mutant (V617F) JAK2, as well as FMS-like tyrosine kinase 3 (FLT3), which was granted accelerated approval by the FDA in February 2022 for the treatment

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP1A2 Inducers
  6. Drug

    Inotersen

    go.drugbank.com/drugs/DB14713
    ApprovedInvestigational

    Inotersen is a transthyretin-directed antisense oligonucleotide for the treatment of the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It was FDA approved in October 2018. Inotersen has been shown to i...

  7. Drug

    Inebilizumab

    go.drugbank.com/drugs/DB12530
    ApprovedInvestigational

    [L52705] In December 2025, the FDA approved an additional indication for generalized myasthenia gravis. [L54838]

  8. Drug

    Poliovirus type 1 antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10795
    ApprovedInvestigational

    Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 1. The v...

    Mixtures: Dt Polio Adsorbed - Sus Im
  9. Drug

    Poliovirus type 3 antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10797
    ApprovedInvestigational

    Poliovirus type 3 antigen is a suspension of poliovirus Type 3 (Saukett) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 3. The v...

    Mixtures: Dt Polio Adsorbed - Sus Im
  10. Drug

    Elafin

    go.drugbank.com/drugs/DB05161
    Investigational

    Elafin is a human protein that is produced naturally in the skin, lung and breast, protecting the respective tissue from destruction by the immune system. Elafin’s ability to block the activity of destructive enzymes that are involved in...